We are a Singapore-headquartered micro ribonucleic acid (miRNA) technology company that is making diagnostic solutions for the screening of diseases accessible across our key markets in Asia, including Singapore and China.

Our story began in early 2000s when our founders pioneered a highly sensitive, specific and robust detection technology for miRNA, the smallest genetic material ever found in human and other living organisms. Realizing the potential of miRNA-based clinical applications in solving unmet needs in cancer, cardiovascular, metabolic, and infectious diseases, we decided to bring our technology from lab to clinic.

In 2014, we spun off from Agency of Science, Technology and Research (A*STAR) to commercialise our technology and develop accurate multi-cancer early detection solutions and make them readily available and accessible to people who need them.

We believe that the future of healthcare will shift from treating the sick to preventive healthcare. Our science and innovation will continue as we are committed to making diagnostic solutions for the early detection of diseases accessible on a global scale.